NCT06976983 · NOT YET RECRUITING
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
This trial is testing whether a wearable magnetic helmet worn at home can reduce the involuntary movements (chorea) that are a hallmark of Huntington's disease. Participants receive either a real device or a placebo version, and neither they nor the researchers know which. It is a Phase NA trial — meaning it focuses on a device, not a drug, but is still an early-stage feasibility and safety test, not a proven treatment.
You may qualify if
- Diagnosis of HD genetically confirmed (number of CAG triplets ≥36)
- Presence of chorea movements quantified with a score ≥ 10 on the sum of the scores of the subscale of the Unified Huntington's Disease Rating Scale (UHDRS) for the evaluation of maximum chorea for the facial, oro-bucco-lingual, truncal, four limbs districts
- Ability to provide written informed consent
- No changes in drug therapy in the 8 weeks prior to the baseline visit
- No changes in drug therapy for the entire duration of the study
You're excluded if
- Contraindications to exposure to magnetic fields
- Patients who are pregnant or breastfeeding
- Presence of significant risk of suicidal behavior
- Patients who have received an investigational drug in a clinical trial within 30 days of the baseline visit or have planned to use such an investigational drug during the study
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-05-16